Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
Rubius Therapeutics’ $200 Million Underwritten Public Offering
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...
Tessera Therapeutics’ $230 million Series B Financing Round
Goodwin Procter LLP advised Tessera Therapeutics on the deal. Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised...